TriSalus Life Sciences (TLSIW) Liabilities and Shareholders Equity (2022 - 2025)
Historic Liabilities and Shareholders Equity for TriSalus Life Sciences (TLSIW) over the last 4 years, with Q3 2025 value amounting to $36.5 million.
- TriSalus Life Sciences' Liabilities and Shareholders Equity rose 3270.37% to $36.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $130.4 million, marking a year-over-year increase of 2732.65%. This contributed to the annual value of $24.0 million for FY2024, which is 254.9% down from last year.
- Latest data reveals that TriSalus Life Sciences reported Liabilities and Shareholders Equity of $36.5 million as of Q3 2025, which was up 3270.37% from $41.3 million recorded in Q2 2025.
- TriSalus Life Sciences' 5-year Liabilities and Shareholders Equity high stood at $251.3 million for Q3 2022, and its period low was $12.2 million during Q2 2023.
- In the last 4 years, TriSalus Life Sciences' Liabilities and Shareholders Equity had a median value of $28.6 million in 2025 and averaged $71.6 million.
- In the last 5 years, TriSalus Life Sciences' Liabilities and Shareholders Equity plummeted by 9511.57% in 2023 and then soared by 16500.69% in 2024.
- Over the past 4 years, TriSalus Life Sciences' Liabilities and Shareholders Equity (Quarter) stood at $22.0 million in 2022, then rose by 11.83% to $24.6 million in 2023, then dropped by 2.55% to $24.0 million in 2024, then surged by 52.11% to $36.5 million in 2025.
- Its Liabilities and Shareholders Equity was $36.5 million in Q3 2025, compared to $41.3 million in Q2 2025 and $28.6 million in Q1 2025.